Fennec Pharmaceuticals Inc. FENC
9.39 USD 0.00 (+0.00%)
At closeNov 5, 2026, 4:00 PM EST
9.39 0.00 0.00%
After hours · Nov 5, 4:00 PM ET
Day range unavailable
5.65 52-week range 13.25
- YTD
- +21.95%
- 1 year
- +13.82%
- Market cap
- 329.28M
- Revenue (ttm)
- 49.35M
- Profit margin
- -2.30%
- EPS (ttm)
- -0.12
- Shares out
- 27.43M
- Forward P/E
- 16.78
- YTD return
- +21.95%
- 1-year return
- +13.82%
- Avg volume
- 190.93K
- Previous close
- 9.39
- 52-week range
- 5.65 – 13.25
- Beta
- 0.27
- Analysts
- Strong Buy
- Price target
- 13.60 (+44.8%)
YTD +1.71 (+22.27%)
Key statistics
- Enterprise value
- 156.10M
- PEG ratio
- 0.00
- Price / sales
- 3.45
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 7.00%
- Free cash flow
- -3.40M
- Total cash
- 40.32M
- Total debt
- 32.10M
- Return on equity
- 0.00%
- Short % of float
- 11.18%
- 50-day average
- 5.08
- 200-day average
- 6.71
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 13.60 +44.8% upside
Now 9.39
- Target (low)
- 12.00
- Target (mean)
- 13.60
- Target (high)
- 15.00
Ratings (0m) 5 5 buy · 0 hold · 0 sell
- Strong buy2
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.12.
Financials — quick view
FENC Revenue — quarterly 17.87M
FENC Net income — quarterly 1.97M
FENC EPS — quarterly 0.06
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.13 | -0.21 | -0.08 | -61.54% |
| Aug 13, 2024 | Jun 1, 2024 | 0.06 | -0.20 | -0.26 | -433.33% |
| May 14, 2024 | Mar 1, 2024 | 0.49 | 0.41 | -0.08 | -16.33% |
| Mar 21, 2024 | Dec 1, 2023 | 0.02 | -0.10 | -0.12 | -600.00% |
| Nov 6, 2023 | Sep 1, 2023 | -0.11 | -0.07 | +0.04 | +36.36% |
| Aug 3, 2023 | Jun 1, 2023 | -0.18 | -0.21 | -0.03 | -16.67% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 17, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 22, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 14, 2024 | Craig-Hallum | main | Buy | Buy |
| May 15, 2024 | Craig-Hallum | main | Buy | Buy |
| May 15, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Apr 4, 2024 | HC Wainwright & Co. | main | Buy | Buy |
About Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- fennecpharma.com
News
Fennec Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 12, 2026 
HC Wainwright & Co. Reiterates Buy on Fennec Pharmaceuticals, Maintains $16 Price Target 
B. Riley Securities Reiterates Buy on Fennec Pharmaceuticals, Raises Price Target to $18 
Wedbush Maintains Outperform on Fennec Pharmaceuticals, Raises Price Target to $16 
Fennec Pharmaceuticals Q2 EPS $0.05 Beats $0.02 Estimate, Sales $17.874M Beat $16.095M Estimate 
HC Wainwright & Co. Maintains Buy on Fennec Pharmaceuticals, Raises Price Target to $16 
Fennec Pharmaceuticals Reports Q1 2026 Results: Full Earnings Call Transcript 
Earnings Scheduled For May 14, 2026 
Wedbush Reiterates Outperform on Fennec Pharmaceuticals, Maintains $13 Price Target - Fennec Pharma Initiates Investigator-Sponsored Study By University Of Arizona Cancer Center To Evaluate Use Of PEDMARK In Adolescent And Young Adult And Adult Patients With Head And Neck And Testicular Cancers Receiving Cisplatin
Your note
Sign in to keep a note on FENC — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ANDRADE ROBERT C | Chief Financial Officer | Stock Award(Grant) | Dec 1, 2024 | 128,423 |
| HAIGH ADRIAN J | Chief Operating Officer | Conversion of Exercise of derivative security | Apr 21, 2024 | 0 |
| ISLAM KHALID | Director | Conversion of Exercise of derivative security | Nov 15, 2023 | 213,825 |
| RALLIS CHRISTOPHER ANIGERON | Director | Conversion of Exercise of derivative security | Dec 1, 2024 | 52,214 |
| RAYKOV ROSTISLAV CHRISTOV | Director | Sale | Dec 4, 2024 | 66,432 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Southpoint Capital Advisors Lp | 14.84% | 4,077,214 | 25.32M | Sep 29, 2024 |
| Sonic Gp LLC | 8.76% | 2,407,357 | 14.95M | Sep 29, 2024 |
| Solas Capital Management, LLC | 7.00% | 1,923,536 | 11.95M | Sep 29, 2024 |
| DG Capital Management, LLC | 5.54% | 1,522,204 | 9.45M | Sep 29, 2024 |
| Blackrock Inc. | 4.48% | 1,229,477 | 7.64M | Sep 29, 2024 |
| Vanguard Group Inc | 3.81% | 1,047,891 | 6.51M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3.19% | 876,208 | 5.44M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.04% | 559,371 | 3.47M | Oct 30, 2024 |
| Fidelity Small Cap Index Fund | 0.88% | 241,018 | 1.50M | Aug 30, 2024 |
| iShares Russell 2000 Value ETF | 0.60% | 165,510 | 1.03M | Oct 30, 2024 |
| Vanguard Russell 2000 Index Fund | 0.34% | 94,580 | 587.34K | Aug 30, 2024 |
| Schwab Capital Trust-Small Cap Index Fund | 0.20% | 55,452 | 344.36K | Jul 30, 2024 |